Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H16N2.ClH |
| Molecular Weight | 236.74 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@H](C1=CN=CN1)C2=CC=CC(C)=C2C
InChI
InChIKey=VPNGEIHDPSLNMU-MERQFXBCSA-N
InChI=1S/C13H16N2.ClH/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13;/h4-8,11H,1-3H3,(H,14,15);1H/t11-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16369581Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021038s027lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16369581
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021038s027lbl.pdf
Dexmedetomide (biologically active dextroisomer of medetomidine) is an alpha2-adrenergic agonist which was approved by FDA for the sedation purposes. Upon administration the drug activates the alpha2 receptors thus inhibiting the release of norepinephrine and terminating the propagation of pain signals. Also it inhibits sympathetic activity and thus can decrease blood pressure and heart rate.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095158 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | PRECEDEX Approved UseDexmedetomidine hydrochloride injection is a relatively selective alpha2-adrenergic agonist indicated for: 1) Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Administer Precedex by continuous infusion not to exceed 24 hours. 2) Sedation of non-intubated patients prior to and/or during surgical and other procedures. Launch Date1999 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30427948/ |
1 μg/kg bw single, intravenous dose: 1 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
DEXMEDETOMIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
107.58 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30427948/ |
1 μg/kg bw single, intravenous dose: 1 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
DEXMEDETOMIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
138 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30427948/ |
1 μg/kg bw single, intravenous dose: 1 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
DEXMEDETOMIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Reliability of goniometry in Labrador Retrievers. | 2002-07 |
|
| Evaluation of the perioperative stress response in dogs administered medetomidine or acepromazine as part of the preanesthetic medication. | 2002-07 |
|
| Effects of medetomidine-midazolam, midazolambutorphanol, or acepromazine-butorphanol as premedicants for mask induction of anesthesia with sevoflurane in dogs. | 2002-07 |
|
| Effect of synthesis parameters of the sol-gel-processed spray-dried silica gel microparticles on the release rate of dexmedetomidine. | 2002-07 |
|
| In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse prefrontal cortex. | 2002-06 |
|
| Dual alpha(2)-adrenergic agonist and alpha(1)-adrenergic antagonist actions of dexmedetomidine on human isolated endothelium-denuded gastroepiploic arteries. | 2002-06 |
|
| Hemodynamics of anesthetized ventilated mouse models: aspects of anesthetics, fluid support, and strain. | 2002-06 |
|
| alpha 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation. | 2002-05-31 |
|
| Cardiopulmonary effects of a medetomidine-ketamine combination administered intravenously in gopher tortoises. | 2002-05-15 |
|
| Quantitative electroencephalography of medetomidine, medetomidine-midazolam and medetomidine-midazolam-butorphanol in dogs. | 2002-05 |
|
| Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. | 2002-05 |
|
| Altered presynaptic function in monoaminergic neurons of monoamine oxidase-A knockout mice. | 2002-05 |
|
| New agents, new monitors, same unanswered questions. | 2002-05 |
|
| Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. | 2002-05 |
|
| alpha(2B)-Adrenergic receptors activate MAPK and modulate proliferation of primary cultured proximal tubule cells. | 2002-05 |
|
| Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. | 2002-04-09 |
|
| Down-regulation of the alpha-2C adrenergic receptor: involvement of a serine/threonine motif in the third cytoplasmic loop. | 2002-04-02 |
|
| Anesthesia of boma-captured Lichtenstein's hartebeest (Sigmoceros lichtensteinii) with a combination of thiafentanil, medetomidine, and ketamine. | 2002-04 |
|
| Postoperative pain control in cats: clinical trials with medetomidine and butorphanol. | 2002-03-09 |
|
| Use of medetomidine for capture and restraint of cassowaries (Casuarius casuaris). | 2002-03 |
|
| Dexmedetomidine may be effective, but is it safe? | 2002-03 |
|
| Infusion of alpha-2-adrenergic agents into the paraventricular and arcuate nuclei of the hypothalamus in the Siberian hamster: opposing effects on basal prolactin. | 2002-03 |
|
| N-Glucuronidation of some 4-arylalkyl-1H-imidazoles by rat, dog, and human liver microsomes. | 2002-03 |
|
| Initial experience with dexmedetomidine in paediatric-aged patients. | 2002-02 |
|
| Some factors influencing the level of clinical sedation induced by medetomidine in rabbits. | 2002-02 |
|
| The use of alpha2-agonists during off-pump coronary artery bypass and the effects of hypothermia. | 2002-02 |
|
| Alpha 2-adrenoceptors in the enteric nervous system: a study in alpha 2A-adrenoceptor-deficient mice. | 2002-02 |
|
| Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. | 2002-02 |
|
| Neurohormonal and metabolic effects of medetomidine compared with xylazine in beagle dogs. | 2002-01 |
|
| Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. | 2002-01 |
|
| alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. | 2002-01 |
|
| Controlled hypotension in children: a critical review of available agents. | 2002 |
|
| Interactions between cutaneous afferent inputs to a withdrawal reflex in the decerebrated rabbit and their control by descending and segmental systems. | 2002 |
|
| [Medetomidine-butorphanol combination anesthesia in the dog]. | 2001-12 |
|
| alpha2A-adrenoceptor stimulation reduces capsaicin-induced glutamate release from spinal cord synaptosomes. | 2001-12 |
|
| Dexmedetomidine decreases extracellular dopamine concentrations in the rat nucleus accumbens. | 2001-11-16 |
|
| Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. | 2001-11 |
|
| Dexmedetomidine: a real innovation or more of the same? | 2001-11 |
|
| Effect of medetomidine on electroencephalography and use of a quantitative electroencephalograph for evaluating sedation levels in dogs. | 2001-11 |
|
| Cardiopulmonary effects of three different anaesthesia protocols in cats. | 2001-11 |
|
| Cardiopulmonary evaluation of the use of medetomidine hydrochloride in cats. | 2001-11 |
|
| Optimization of intraperitoneal injection anesthesia in mice: drugs, dosages, adverse effects, and anesthesia depth. | 2001-10 |
|
| New agents for sedation in the intensive care unit. | 2001-10 |
|
| Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. | 2001-10 |
|
| Benzodiazepines in the intensive care unit. | 2001-10 |
|
| Dexmedetomidine infusion and somatosensory evoked potentials. | 2001-10 |
|
| Clinical comparison of preanaesthetic intramuscular medetomidine and dexmedetomidine in domestic sheep. | 2001-10 |
|
| Dextromethorphan and dexmedetomidine: new agents for the control of perioperative pain. | 2001-08 |
|
| Effects of reduced sympathetic activity on myocardial metaiodobenzylguanidine (MIBG) washout. | 2001-06 |
|
| Noradrenergic regulation of hippocampal place cells. | 2001 |
Patents
Sample Use Guides
For Adult Intensive Care Unit Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour. For Adult Procedural Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15795144
Strips of pregnant human myometrium obtained from six individuals at elective caesarean section were incubated with dexmedetomidine (1x10(-11) to 1x10(-6) g/mL) and the in vitro effect was studied as the drug may be used in obstetric anaesthesia
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EMA VETERINARY ASSESSMENT REPORTS |
SEDADEX [AUTHORIZED]
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
CEPEDEX (AUTHORISED)
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
SEDADEX [AUTHORIZED]
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
SILEO [AUTHORIZED]
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
DEXDOMITOR (AUTHORISED)
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
DEXDOR (AUTHORIZED: CONSCIOUS SEDATION)
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
DEXDOMITOR (AUTHORISED)
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
CEPEDEX (AUTHORISED)
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1179333
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
31472
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
SUB20317
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
6918081
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
228054
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID40873215
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL778
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
100000092060
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
145108-58-3
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
DBSALT001013
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
1018WH7F9I
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
C72738
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
m4218
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
1018WH7F9I
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY | |||
|
LL-19
Created by
admin on Mon Mar 31 18:11:30 GMT 2025 , Edited by admin on Mon Mar 31 18:11:30 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD